Characteristics and survival of patients with advanced cancer and p53 mutations. by Said, Rabih et al.
UC San Diego
UC San Diego Previously Published Works
Title


















eScholarship.org Powered by the California Digital Library
University of California
Oncotarget3871www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 5, No. 11
Characteristics and survival of patients with advanced cancer 
and p53 mutations
Rabih Said1,2, Yang Ye1, David S. Hong1, Filip Janku1, Siqing Fu1, Aung Naing1, 
Jennifer J. Wheler1, Razelle Kurzrock1,3, Christoforos Thomas4, Gary A. Palmer5, 
Kenneth R. Hess6, Kenneth Aldape7 and Apostolia M. Tsimberidou1
1 Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson 
Cancer Center, Houston, TX 
2 Department of Internal Medicine, Oncology Division, The University of Texas Health Sciences Center, Houston, TX 
3 Center for Personalized Therapy and Clinical Trials, University of California San Diego - Moores Cancer Center, San Diego, 
CA 
4 Department of Biology and Biochemistry, University of Houston, Houston, Texas 
5 Foundation Medicine, Cambridge, MA 
6 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 
7 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 
Correspondence to: Apostolia-Maria Tsimberidou, email: atsimber@mdanderson.org
Keywords: p53 mutations, matched therapy, molecular aberrations
Received: February 21, 2014 Accepted: May 23, 2014 Published: May 25, 2014
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT
P53 mutations are associated with invasive tumors in mouse models. We 
assessed the p53 mutations and survival in patients with advanced cancer treated 
in the Phase I Program. Of 691 tested patients, 273 (39.5%) had p53 mutations. 
Patients with p53 mutations were older (p<.0001) and had higher numbers of liver 
metastases (p=.005). P53 mutations were associated with higher numbers of other 
aberrations; PTEN (p=.0005) and HER2 (p=.003) aberrations were more common 
in the p53 mutation group. No survival difference was observed between patients 
with p53 mutations and those with wild-type p53. In patients with wild-type p53 
and other aberrations, patients treated with matched-therapy against the additional 
aberrations had longer survival compared to those treated with non-matched-therapy 
or those who received no therapy (median survival, 26.0 vs. 11.8 vs. 9.8 months, 
respectively; p= .0007). Results were confirmed in a multivariate analysis (p= .0002). 
In the p53 mutation group with additional aberrations, those who received matched-
therapy against the additional aberrations had survival similar to those treated with 
non-matched-therapy or those who received no therapy (p=.15). In conclusion, our 
results demonstrated resistance to matched-targeted therapy to the other aberrations 
in patients with p53 mutations and emphasize the need to overcome this resistance.
INTRODUCTION
The tumor suppressor protein p53 is activated in 
response to a variety of stress signals to ensure genome 
stability in cells. The role of p53 in guarding the cell 
reflects its ability to act as a potent transcriptional 
activator, regulating the expression of genes that inhibit 
cell cycle progression or induce apoptosis or senescence. 
By eliciting cell growth inhibition, p53 functions to 
prevent cancer development [1]. In addition to its role 
in suppressing tumor growth, p53 can limit cancer 
progression by decreasing the invasiveness and metastatic 
capacity of cancer cells [2-4]. 
Loss of p53 function occurs frequently in human 
cancers and results from mutations in the p53 gene or 
defects in the pathway that activates p53 [1]. More than 
75% of p53 mutations lead to the expression of a full-
length protein with a single amino acid substitution. 
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In most cases, these mutant p53 proteins lose wild-
type functions, elicit dominant-negative effects on 
the remaining wild-type p53, or acquire oncogenic 
functions [5-7]. This gain-of-function phenotype has been 
characterized in in vivo studies. Mice that carry mutant 
p53 develop different types of tumors with more invasive 
phenotypes than the p53-null mice in which the p53 
protein is not expressed [6, 8]. In addition, the analysis 
of cell culture models has identified several oncogenic 
properties of mutant p53, including its ability to promote 
migration, invasion, angiogenesis, and chemoresistance 
[2-4, 7, 9, 10]. The single amino acid substitutions in the 
p53 protein are divided into two broad classes: structural 
and contact DNA mutations. Most of the point mutations, 
including those at amino acids R175, G245, R248, R249, 
R273 and R282, tend to cluster at hot spots within the 
DNA-binding domain. Contact hot spot mutations lead 
to the loss of DNA binding activity and subsequent 
alterations in the transcriptional activity of p53. Structural 
hot spot mutations cause unfolding of the p53 protein that 
affects its interaction with other proteins. Mutant p53 has 
been shown to elicit its oncogenic actions by interacting 
with and inhibiting its family members, p63 and p73. 
Mutant p53 is known to alter the expression of p63 
target genes, and this has been associated with enhanced 
invasive behavior [7]. In addition, oncogenic mutations 
that activate the Ras signaling pathway inhibit the function 
of p63 by promoting its interaction with mutant p53. By 
regulating the activity of mutant p53, oncogenic Ras 
induces the development of prometastatic phenotypes[11, 
12]. 
Several studies have investigated the importance 
of p53 mutation status in predicting clinical outcome in 
various types of cancer. Some of the p53 mutations have 








   Female 141 (52) 236 (56) 377 (55)
   Male 132 (48) 182 (44) 314 (45)
Age .01
   >60 130 (48) 159 (38)
Race .6
    White 207 (76) 318 (76) 525 (76) 
    Hispanic 29 (11) 37 (9) 66 (10)
    Black 27 (10) 39 (9) 66 (10)
    Asian 8 (2) 18 (4) 26 [16]
    Unknown 2 (1) 6 (2) 8 (1)
Tumor type NA
    CRC 49 (18) 52 (12) 101 (15)
    Ovarian 31 (11) 27 (7) 58 (8)
    GI, other 29 (11) 28 (7) 57 (8)
    Breast 22 (8) 43 (10) 65 (9)
    GYN, other 18 (7) 17 (4) 35 [16]
    Lung 18 (7) 22 [16] 40 (6) 
    Genitourinary 17 (6) 29 (8) 46 (7)
    Head and neck 15 [16] 53 (12) 68 (10)
    Sarcoma 9 [16] 45 (11) 54 (8)
    Endometrial 9 [16] 12 [16] 21 [16]
    Melanoma 8 [16] 22 [16] 30 (4)
    Pancreatic 5 (2) 9 (2) 14 (2)
    Thyroid 4 (1) 9 (2) 13 (2)
    Other 39 (14) 50 (12) 89 (13)
ECOG score .23
    0 69 (25) 128 (31) 197 (29)
    1 180 (66) 247 (59) 427 (62) 
    2 19 (7) 35 (8) 54 (8)
    3 3 (1) 1 (-) 4 (1)
    Unavailable 2 (1) 7 (2) 9 (1)
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been correlated with shorter survival or a poorer response 
to treatment in several cancers[13]. In addition, some 
mutations were correlated with worse survival than other 
mutations. For example, mutations in the DNA-binding 
domain of p53 have been associated with worse prognosis 
and poorer response to chemotherapy [14]. 
We have previously reported the clinical 
characteristics and response to standard systemic therapy 
of 145 patients with documented p53 mutational status 
(n=66 mutated vs. n=79 wild-type tumors) who were 
referred to our department for participation in Phase I 
clinical trials[15]. In the current study, we assessed the 
frequency of various p53 mutations and their effects on 
clinical outcomes in a larger number of patients with 
advanced cancer who were referred for treatment to the 
Phase I Clinical Trials Program at The University of 
Texas MD Anderson Cancer Center. We also evaluated 
the impact on clinical outcomes of additional targetable 
aberrations in patients with and without p53 mutations.
RESULTS
Demographics
From May 2010 to April 2013, 691 patients were 
found to have tumor tissue tested for p53 mutation status. 
Of these, 273 (39.5%) had p53 mutations and 418 (60.5%) 
had wild-type p53. The patients’ baseline characteristics 
by p53 mutation status are shown in Table 1a and Table 
1b. Patients with p53 mutations were older (median age, 
59 vs. 55 years, p<.0001) and were more likely to have 
liver metastases (108/273 [33%] vs. 122/418 [29%], 
p=.005) compared to patients with wild-type p53. 
No difference between the two groups was observed 
in sex, race, performance status, number of metastatic 
sites, number of prior therapies, serum albumin and lactate 
dehydrogenase levels, and Royal Marsden Hospital score. 
The most common tumor types seen were colorectal, head 
and neck, and breast cancers, which reflected the referral 
pattern of patients in the Phase I Clinic. Colorectal cancer 
was the most common malignancy in both groups (wild-
type, n=49 [18%] and mutant, n=52 [12.5%]).
Distribution of p53 Mutations
Of 273 patients with p53 mutations, 17 (6%) 
had more than one p53 mutation. The distribution of 
p53 mutations by exons, codons, and tumor types is 
summarized in Table 2. Of the 273 patients, 239 (84%) 
had mutations within the DNA-binding domain, with the 
following distribution: exon 5 (n=73, 27%), exon 6 (n=45, 
16%), exon 7 (n=63, 23%), and exon 8 (n=58, 21%). 
Mutations within other exons were found in 47 (17%) 
patients. P53 mutations within exon 5 were more common 
in colorectal cancer, whereas mutations within exons 6, 7, 
and 8 were more common in lung, pancreatic, and ovarian 
cancer, respectively. Mutations within other exons were 
more common in various gynecological, breast, and 
Table 1b: Characteristics of patients with wild-type and mutant p53 tumors
Albumin .55
   ≥ 3.5 g/dL 238 (87) 369 (88) 607 (87) 
   <3.5 g/dL 26 (10) 47 (11) 73 (10)
   Unavailable 9 [16] 4 (1) 23 [16]
LDH .35
   >618 U/L 90 (33) 128 (31) 218 
   ≤618 U/L 172 (63) 286 (68) 458 
   Unavailable 11 (4) 4 (14) 27 
RMH score .59
    0 126 (46) 212 (51) 338 (49) 
    1 87 (32) 123 (29) 210 (30)
    2 42 (16) 69 (17) 111 (16)
    3 6 (2) 9 (2) 15 (2)
    Unknown 12 (4) 5 (1) 17 [16]
Liver metastases 108 (40) 122 (29) 230 (33) .005
Number of metastatic 
sites
   Median (Range) 2 (0-8) 2 (0-7) 2 (0-8) .15
Number of prior 
therapies
   Median (Range) 3 (0-10) 3 (0-13) 3 (0-10) .16
Abbreviations: CRC-colorectal, GI-gastrointestinal, GYN-gynecological, ECOG-Eastern 
Cooperative Oncology Group, LDH-lactate dehydrogenase, RMH-Royal Marsden Hospital.
Oncotarget3874www.impactjournals.com/oncotarget
genitourinary tumors (Supplemental - Figure 1e). 
When all screened patients were considered, 
p53 mutations in the hot-spot codons (175, 245, 248, 
249, 273, and 282) were significantly more common in 
colorectal cancer (19/101, 19%) than in the other tumor 
types (33/580, 6%). When the analysis was limited to 
patients with p53 mutations, 24 (49%) patients with 
colorectal cancer had hot-spot mutations compared to 60 
(27%) patients with the remaining tumor types (p=.0002). 
Mutations in the DNA-binding domain excluding the hot-
spot codons were more commonly seen in ovarian and 
lung cancer (Supplemental-Figure 1a-1g).
Other Aberrations
We examined aberrations other than p53 in patients 
with p53 mutations and wild-type p53. Additional 
aberrations were found more often in the group with p53 
mutations than in the wild-type p53 group (p=.002). The 
distribution of the number of other aberrations in the two 
groups is summarized in Table 3. Interestingly, PTEN loss 
or mutation was found more often in tumors with p53 
mutations than in those with wild-type p53 (23% vs. 5%, 
p=.0005). Similarly, HER2 aberrations were significantly 
more common in tumors with p53 mutations than in those 
with wild-type p53 (8% vs. 2%, p=.003). Alternatively, 
there was a trend toward a higher percentage of BRAF 
mutations in the patients with wild-type p53 compared 
with those with mutated p53 (6% vs. 2%, p=. 07). 
The distribution of the common additional 
aberrations in the groups of patients with mutant and wild-
type p53 is summarized in Table 4. The most common 
additional aberrations seen in the mutant p53 group were 
PTEN (23%), KRAS (16%), APC (12%), and PI3K (10%). 
The most common aberrations seen in the wild-type p53 
group were KRAS (16%), PI3K (14%), and PTEN (9%). 
Overall, aberrations involved in the RAS/RAF/MEK 
pathway were more frequent in the p53 mutant group 
than in the wild-type p53 group (59/142 [42%] vs. 81/258 
[31%], respectively; p=.04). In contrast, no difference was 
observed between the two groups in aberrations involving 
the PI3K/AKT/mTOR pathway (56/142 [39%] vs. 88/258 
[34%], respectively; p=.29). 
Treatment
Of the 273 patients with p53 mutations, 195 (71%) 
were treated on various phase I clinical trials; among them, 
20 (7%) patients received local therapy, including various 
hepatic arterial infusion and intra-peritoneal therapy 
regimens. The remaining 78 (29%) patients did not receive 
any treatment for various reasons. Of 418 patients with 
wild-type p53, 312 (75%) were treated on various phase 
I clinical trials; among them, 26 (6%) patients received 
local therapy. The remaining 106 (25%) patients did not 
receive any therapy. The reasons for which patients did not 
Table 2: Distribution of p53 mutations by exons, codons, and tumor types
Exon Location* Codon Location*

















(20) 7 (14) 24 (49) 20 (41) 5 (10)
Ovarian (n=31) 9 (29) 4 (13) 4 (13) 10 (32) 4 (13) 7 (23) 21 (68) 3 (10)
GI, other (n=29) 9 (31) 2 (7) 10 (35) 7 (24) 4 (14) 8 (28) 22 (76) 2 (7)
Lung (n=18) 6 (33) 6 (33) 2 (11) 2 (11) 2 (11) 3 (17) 13 (72) 2 (11)
Genitourinary (n=17) 3 (18) 3 (18) 4 (23) 4 (23) 4 (23) 4 (24) 10 (59) 4 (24)
GYN, other (n=18) 2 (11) 4 (22) 3 (17) 5 (28) 4 (22) 6 (33) 9 (50) 3 (16)
Head and neck (n=15) 3 (20) 4 (26) 4 (26) 2 (13) 3 (20) 3 (20) 12 (80) 2 (13)
Breast (n=22) 7 (32) 2 (9) 3 (14) 5 (23) 6 (27) 6 (27) 14 (64) 5 (23)
Sarcoma (n=9) 3 (33) 1 (11) 0 3 (33) 2 (22) 1 (11) 6 (66) 2 (22)
Endometrial (n=9) 3 (33) 1 (11) 4 (44) 0 1 (11) 3 (33) 5 (56) 1 (11)
Melanoma (n=8) 2 (25) 4 (50) 1 (12) 0 2 (25) 2 (25) 6 (75) 2 (25)
Pancreatic (n=5) 0 1 (20) 3 (60) 1 (20) 0 2 (40) 3 (60) 0
Thyroid (n=4) 0 0 1 (25) 2 (50) 1 (25) 1(25) 2 (50) 1 (25)
Other (n=39) 10 (26) 7 (18)
13 
(33) 8 (20) 7 (18) 10 (26) 26 (67) 7 (18)






(22) 47 (17) 80 (29) 169 (62) 39 (14)
* Tumors can have more than 1 mutation in different exon and codon locations. Abbreviations: GI-gastrointestinal, 
GYN-gynecological.  
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receive treatment were ineligibility or unavailability of a 
clinical trial (n=44, 24%), insurance issues (n=9, 5%), and 
personal reasons (n= 131, 71%).
Among patients with additional aberrations in the 
p53 mutation group, 37 (26%) patients received targeted 
therapy against the additional aberrations, 62 (43%) 
patients received non-matched therapy, and 44 (31%) 
patients received no therapy. In the wild-type p53 group, 
78 (30%) patients received targeted therapy against the 
additional aberrations, 117 (45%) patients received non-
matched therapy, and 63 (25%) patients received no 
therapy.
Table 3: Number of other aberrations associated with wild-type and 
mutant p53






   0 88 (32.2) 162 (38.8)
.0018
   1 79 (28.9) 134 (32.1)
   2 38 (13.9) 68 (16.3)
   3 19 (7.0) 29 (6.9)
   ≥4 49 (18) 25 (6)
Table  4: Distribution of the most common other mutations associated with both 
wild-type and mutant p53 status
P53 mutation (N=273) P53 wild-type (N=418) P
Tested Positive % Tested Positive %
PTEN* 93 21 23 336 31 9 .0005
PIK3CA 263 26 10 388 55 14 .10
BRAF 250 6 2 329 18 6 .07
KRAS§ 255 40 16 363 57 16 1.0
EGFR§ 241 9 4 334 7 2 .24
c-Met 254 9 4 370 11 3 .69
HER2§ 209 16 8 313 7 2 .003
APC 119 14 12 163 12 7 .21
*: PTEN loss by immunohistochemistry or mutation
§: Mutation or amplification.
Figure 1: a Overall survival of patients with mutant p53 tumors by whether they did or did not receive any treatment in phase 
I. Of 188 patients treated with phase 1 trials the median overall survival was 14.6 months. Of 85 patients non-treated the median overall 
survival was 7.2 months.b. Overall survival of patients with wild-type p53 tumors by whether they did or did not receive any treatment in 
phase I. Of 300 patients treated with phase 1 trials the median overall survival was 15.8 months. Of 118 patients non-treated the median 
overall survival was 9.3 months.
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Overall Survival
There was no difference in overall survival between 
patients with p53 mutations and those with wild-type p53 
(median survival, 14 months, 95% confidence interval: 11-
17, for both groups; hazard ratio = 1.0, 95% confidence 
interval: 0.8-1.3; p=.71). The overall survival of treated 
and untreated patients with p53 mutations is shown in 
Figure 1a. The median survival durations were 14.6 
months and 7.2 months, respectively (p=.006). The overall 
survival of treated and untreated patients with wild-type 
p53 is shown in Figure 1b. The median survival durations 
were 15.8 months and 9.3 months, respectively (p=.0002).
The overall survival of patients with p53 mutations 
by exon is shown in Supplemental-Figure 2. The median 
overall survival durations for exon 5, 6, 7, and 8 mutations 
were 9.5, 13.6, 15.7, and 17.6 months, respectively 
(p=.31). 
Overall Survival by p53 Status and Additional 
Aberrations
We performed survival analyses of patients with p53 
mutations and additional aberrations. The median survival 
durations were 13.6 months in patients who received 
matched therapy (n= 37), 13.9 months in those who 
received non-matched therapy (n= 62), and 7.6 months in 
those who received no treatment (n= 44) (p= .06; Figure 
2a). In multivariate analyses (in which performance status 
[0 vs. ≥1], serum albumin level [<3.5 g/dL vs. ≥3.5 g/dL], 
lactate dehydrogenase level [<617 U/L vs. ≥617 U/L], 
number of metastatic sites [0-2 vs. ≥3], liver metastases, 
and number of prior treatments [0-3 vs. ≥4] were taken 
into consideration), no significant difference in survival 
was noted among the three groups (p = 0.15). 
In patients with wild-type p53 and other aberrations, 
those treated with matched therapy (n= 78) had longer 
survival than those treated with non-matched therapy (n= 
117) or those who received no treatment (n= 63) (median 
survival, 26.0 vs. 11.8 vs. 9.8 months, respectively; p= 
.0007; Figure 2b). 
A multivariate analysis (after adjustment for the 
variables listed above) confirmed this difference between 
the treatment groups (p=.0002). These findings translated 
into longer survival for the patients with a more number 
of additional mutations in the wild-type p53, but not the 
mutant p53 group (Supplemental-Figure 3a and 3b). 
DISCUSSION
This analysis expands on our previous report 
on the characteristics and survival of patients with 
advanced cancer and p53 mutations. In the current study, 
we evaluated the effects of specific p53 mutations and 
additional aberrations on survival in patients referred to 
the Phase I Clinical Trials Program. P53 mutations were 
associated with higher numbers of other aberrations and 
resistance to targeted therapy. P53 status did not affect 
overall survival in this patient population, but matched 
therapy for other aberrations was associated with longer 
survival in patients with wild-type p53. P53 mutations 
varied by tumor type and were associated with higher 
proportions of PTEN and HER2 aberrations than wild-
type p53. 
Overall, 39.5% of the patients analyzed had a 
p53 mutation. Patients with p53 mutations were older 
(p<.0001) and had higher rates of hepatic metastases 
(p=.005) than patients with wild-type p53. P53 mutations 
within exon 5 were more common in colorectal cancer, 
Figure 2: a Overall survival of patients with mutant p53 tumors by whether they received matched targeted therapy (n=37)-, 
non-matched (n=62)-, or no therapy (n=44) for the other aberrations with a median survival of 13.6, 13.9 and 7.6 months, 
respectively. b.Overall survival of patients with wild-type p53 tumors by whether they received matched targeted therapy (n=78)-, non-
matched (n=117)-, or no therapy (n=63) for the other aberrations with a median survival of 26, 11.8 and 9.8 months, respectively.
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while mutations within exons 6, 7, and 8 were more 
common in lung, pancreatic, and ovarian cancer, 
respectively. 
Our findings of older age, more frequent liver 
metastases, and more frequent PTEN loss in the p53-
mutated group in the current, more extensive analysis, 
were similar to those in our prior analysis [15]. 
Our results are consistent with previously known 
data showing that the percentage of p53 mutation varies 
by tumor type and ranges from 10% to 80% [16]. Our 
results are also in line with a previous study showing that 
p53 mutations occurred more frequently in older patients 
with rectal cancer [17]. Other investigators have reported 
that breast cancers harboring p53 mutations occur more 
often in young women (age ≤40 years at diagnosis)[18]. 
In the latter study p53 mutations were found in 63.8% of 
patients, and the percentage of patients with triple negative 
breast cancer was not reported. 
The observation that patients with p53 mutations 
had more liver metastases may be partially explained by 
the role of mutant p53 in promoting cell migration and 
invasion [19], as shown in preclinical models [11, 20]. 
A previous study showed that patients with colorectal 
cancer with p53 mutations had a larger number of hepatic 
metastases than patients with wild-type p53 tumors [21]. 
The distribution of various types of p53 mutations 
in our study varies by tumor type. This difference may 
contribute to the variable prognostic value of p53 
mutations in various tumor types with p53 mutations [13].
In our series, tumors with p53 mutations had more 
additional aberrations than tumors with wild-type p53 
(p=.002) (Table 3). We found that loss of PTEN or PTEN 
mutation (23% vs. 5%, p=.0005) and HER2 aberrations 
(8% vs. 2%, p=.003) were more common in tumors with 
p53 mutations than in those with wild-type p53. These 
results may be due in part to the role of p53 in maintaining 
genomic integrity in mammalian cells, as previously 
described [22]. The frequency of PTEN aberrations in 
tumors with p53 mutations further supports the need for 
“individualized” treatment targeting the PI3K/AKT/PTEN 
pathway in prospective clinical trials. 
No difference in survival was observed between 
patients with p53 mutations and those with wild-type p53 
(p=0.71). In both groups, the overall survival duration 
was longer in patients who received treatment than in 
those who did not. However, among patients with wild-
type p53 and other aberrations, survival was superior in 
those who received matched therapy against the additional 
aberrations compared to non-matched therapy. We have 
previously published evidence that identifying specific 
molecular abnormalities and choosing therapy based on 
these abnormalities is associated with a longer time to 
treatment failure in the phase I setting than that of previous 
systemic therapy. Furthermore, in the non-randomized 
setting, rates of response, time to treatment failure, and 
survival were higher with matched targeted therapy than 
with non-matched therapy [23]. 
An intriguing finding in the current report is the 
observation that patients with wild-type p53 and other 
aberrations who received matched therapy against these 
aberrations had longer survival than those treated with 
non-matched therapy or those who received no treatment 
(median survival, 26 vs. 11.8 vs. 9.8 months, respectively; 
p=.0007). This survival advantage was confirmed in 
multivariate analysis after adjustment for other covariates 
(p=.0002). In contrast, in the p53 mutation group with 
additional aberrations, the survival durations were similar 
for those who received matched therapy against the 
additional aberrations, those treated with non-matched 
therapy, and those who received no therapy (median 
survival, 13.6 vs. 13.9 vs. 7.6 months, respectively; 
p=.06). 
The exact role of p53 in the context of other 
molecular aberrations and their prognostic significance 
in various tumor types needs to be elucidated. Whether 
p53 mutations are driver mutations or contribute to the 
emergence of resistance to targeted agents needs to be 
evaluated. Resistance to therapy seen in tumors with 
p53 mutation requires the development of new agents or 
strategies. Several investigators have reported that p53-
based cyclotherapy may represent a successful strategy. 
[24-30] This approach is based on protection of normal 
cells from chemotherapy-induced adverse events. Low-
doses of p53 activators, such as nutlin-3 and actinomycin 
D, are used to induce p53-dependent cell cycle arrest in 
normal cells bearing wild-type p53. [24-30] Prospective 
clinical trials are needed to explore the role of this 
approach in overcoming p53 resistance.
Our data suggest that the identification of driver 
mutations in patients with wild-type p53 and other 
aberrations and the selection of targeted therapy may 
contribute to improved survival. Recently published 
data in head and neck squamous cell carcinoma also 
demonstrated that PI3K/Akt/mTOR inhibition using PF-
04691502 is enhanced with induction of wild-type p53 
in human xenograft and murine knockout models [31]. 
The authors concluded that p53 is one of the potential 
modifiers of response (in addition to PI3KCA, PTEN, 
TGF-β alterations) [31]. 
In conclusion, our data add to the published data 
demonstrating that p53 mutations are associated with 
a poor prognosis and resistance to treatment, and they 
emphasize the need to develop agents or strategies to 
overcome this resistance. These findings further support 
the need to individualize cancer therapy and should be 




We reviewed all patients who underwent testing for 
p53 mutation status in the Department of Investigational 
Cancer Therapeutics at MD Anderson Cancer Center. 
Molecular profiling was performed on available tissue 
samples from consecutive patients with advanced tumors 
referred to the Clinical Center for Targeted Therapy. 
Patients were of various ages and had advanced or 
metastatic cancer that was refractory to standard therapy, 
that had relapsed after standard therapy, or for which there 
was no standard therapy available. All protocols required 
that participants have evidence of evaluable or measurable 
disease according to Response Evaluation Criteria in 
Solid Tumors (RECIST) guidelines [32, 33] and an 
Eastern Cooperative Oncology Group performance status 
of 0-2. Additional eligibility criteria varied by protocol. 
All patients provided written informed consent prior to 
enrollment in a trial. All trials, as well as this analysis, 
were performed with the approval of and in accordance 
with the guidelines of the MD Anderson Institutional 
Review Board. 
Analysis of Molecular Aberrations
The p53 mutation status was determined by either 
polymerase chain reaction–based or next-generation 
sequencing in a Clinical Laboratory Improvement 
Amendments–certified laboratory, as previously described 
[23]. The next-generation sequencing included 182 genes 
in targeted next-generation sequencing Foundation One 
platform (Foundation Medicine, Cambridge, MA).
Therapy
Treatment was selected as previously published 
[23]. Briefly, the allocation of patients to investigational 
treatment varied over time according to protocol 
availability, eligibility criteria, histologic diagnosis, the 
patient’s prior response to therapy, potential toxicity, 
insurance coverage, and patient preference or physician 
choice. The assignment to a clinical trial was determined 
after clinical, laboratory, and pathologic data from 
all available patient records were reviewed. Patients 
whose tumors had a molecular aberration were treated 
on a clinical trial with a matched targeted agent, when 
available.
Endpoints and Statistical Methods
Patients’ characteristics were analyzed using 
descriptive statistics. Categorical data were described 
using contingency tables, including counts and 
percentages. Continuously scaled measures were 
summarized by median and range. The association 
between two categorical variables was examined using 
the chi-square test. Survival and hazard functions were 
estimated using the Kaplan-Meier method, and survival 
between groups was compared using the two-sided log-
rank test. Survival was analyzed according to the type of 
p53 mutations and the treatment. Hazard ratios with and 
without adjustment for potential confounding variables 
were estimated using Cox proportional hazard regression 
analysis. 
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